Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | NAPRT | Q6XQN6 | 2/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11080330 | 0.87 | GRM6 (0.40) | G6PDCASP7CASP6ALOX15MMP2 | |
| SCHEMBL7540608 | 0.86 | PARP1 (0.41) | GRM6SLC7A5ALDH1A1HSD17B10KDM4E | |
| SCHEMBL6542697 | 0.84 | ALDH1A1 (0.46) | G6PDCASP7CASP6ALOX15MMP2 | |
| SCHEMBL7350764 | 0.83 | CA12 (0.38) | G6PDCASP7CASP6GRM6SLC7A5 | |
| SCHEMBL2940954 | 0.83 | G6PD (0.55) | G6PDCASP7CASP6GRM6SLC7A5 | |
| SCHEMBL27887677 | 0.83 | CYP2D6 (0.45) | GRM6SLC7A5ALDH1A1MYCHSD17B10 | |
| SCHEMBL31011138 | 0.83 | G6PD (0.55) | G6PDCASP7CASP6GRM6SLC7A5 | |
| SCHEMBL722115 | 0.82 | ALDH1A1 (0.56) | ALOX15GRM6ALDH1A1MYCHSD17B10 | |
| SCHEMBL30339401 | 0.82 | ALDH1A1 (0.56) | ALOX15GRM6ALDH1A1MYCHSD17B10 | |
| SCHEMBL11087056 | 0.82 | GRM6 (0.36) | G6PDCASP7CASP6ALOX15GRM6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | Lee Moffitt Cancer Center and Research Institute, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-20240358735-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-10-31 | — | — | US | disclosed |
| WO-2024182664-A1 | MODIFIED RNA COMPOSITIONS AND RELATED METHODS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-4392037-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | Boyce Thompson Institute for Plant Research Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2023-07-20 | — | — | US | disclosed |
| WO-2023028350-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | BOYCE THOMPSON INSTITUTE FOR PLANT RESEARCH, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| CN-109153644-B | Small molecules against CEREBLON to enhance effector T cell function | H·李·莫菲特癌症中心研究有限公司 | 2022-10-21 | — | — | CN | disclosed |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| EP-3909969-A1 | PEPTIDE FOR HYDROGEL FORMATION | Freie Universität Berlin (DE) | 2021-11-17 | — | — | EP | disclosed |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2021-06-17 | — | — | US | disclosed |
| EP-0906333-B1 | SUBSTRATES AND INHIBITORS OF PROTEOLYTIC ENZYMES | MEDIVIR UK LTD (GB) | 2001-07-25 | — | — | EP | disclosed |
| EP-1105135-A1 | ANTIVIRAL INDOLEOXOACETYL PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-13 | — | — | EP | disclosed |
| US-6180114-B1 | A DEVICE-FREE METHOD BY WHICH LIGANDS, SUCH AS DRUGS, CAN BE RELEASED INTO THE BODY, PARTICULARLY IN CONTINUOUS MANNER THROUGH ASSOCIATION WITH HIGH AXIAL RATIO MICROSTRUCTURES (HARMS) | UNIVERSITY OF WASHINGTON | 2001-01-30 | — | — | US | disclosed |
| WO-2000076521-A1 | ANTIVIRAL INDOLEOXOACETYL PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| US-5981749-A | Process for producing isatoic anhydrides | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1999-11-09 | — | — | US | disclosed |
| US-5973145-A | Process for producing isatoic anhydrides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1999-10-26 | — | — | US | disclosed |
| US-5885816-A | OPTICALLY RESOLVING A RACEMIC MIXTURE OF AMINO ACID DERIVATIVES, COMPRISING USING A NONSPECIFIC CATALYTIC ANTIBODY WHICH ENANTIOSELECTIVELY HYDROLIZES VARIOUS AMINO ACID ESTER DERIVATIVES | PROTEIN ENGINEERING RESEARCH INSTITUTE (JP) | 1999-03-23 | — | — | US | disclosed |
| US-5851536-A | Therapeutic delivery using compounds self-assembled into high axial ratio microstructures | UNIVERSITY OF WASHINGTON (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0781767-A1 | Process for producing isatoic anhydrides | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1997-07-02 | — | — | EP | disclosed |
| EP-0765940-A1 | CATALYTIC ANTIBODY WHICH HYDROLYZES AMINO ACID ESTER DERIVATIVE ENANTIOSELECTIVELY | PROTEIN ENGINEERING RESEARCH INSTITUTE (JP) | 1997-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12564583-B2 | Small molecules against cereblon to enhance effector T cell function | CRBN, CD4, ICOS | G6PD 2148/4885CASP7 836/4885CASP6 2048/4885 |
| US-20240358735-A1 | THERAPEUTIC COMPOSITIONS AND RELATED METHODS | MAG, PMP22, B3GAT3 | G6PD 706/4885CASP7 1274/4885CASP6 2621/4885 |
| US-11395820-B2 | Small molecules against cereblon to enhance effector t cell function | CD4, GZMB, CRBN | G6PD 1371/4885CASP7 630/4885CASP6 793/4885 |
| US-20230226035-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, CRBN, GZMB | G6PD 1454/4885CASP7 486/4885CASP6 487/4885 |
| US-20210177825-A1 | SMALL MOLECULES AGAINST CEREBLON TO ENHANCE EFFECTOR T CELL FUNCTION | CD4, GZMB, CRBN | G6PD 1371/4885CASP7 630/4885CASP6 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.